推荐产品
描述
Monophosphoryl Lipid A (Synthetic) (PHAD®)
检测方案
>99% (HPLC)
形式
powder
包装
pkg of 1 × 1 mg (699800P-1mg)
pkg of 1 × 5 mg (699800P-5mg)
制造商/商品名称
Avanti Polar Lipids
应用
vaccine development
运输
dry ice
储存温度
−20°C
一般描述
单磷酰脂质A(MPLA)可从细菌类脂A中提取或通过化学法合成。
通过在感染前产生病原体特异性免疫应答，接种疫苗被公认为预防感染的有效方法。通常，单独使用疫苗抗原进行免疫接种并不能够诱导稳健或持久的免疫反应——导致抵抗感染的保护性免疫失败。因此，需要佐剂增强免疫后的细胞或体液免疫应答。由于已证明使用类脂 A 的疫苗佐剂在动物和人疫苗中诱导异源蛋白的 Th-1 类型免疫应答安全有效，Avanti 开发了磷酸化六酰基二糖 (PHAD ®)，这是第一种可用作人疫苗佐剂的全合成单磷酸化类脂 A。
应用
PHAD单磷酰脂质A®已用于：
- 作为钴卟啉-磷脂(Co-PoP)脂质体组分，用于使用gp41包膜蛋白的近膜端外部区(MPER)免疫小鼠
- 与双十八烷基二甲基溴化铵(DDA)共同作为佐剂，用于基于沙眼衣原体重组膜蛋白的多亚单位疫苗
- 用作呼吸道合胞病毒(RSV)融合(F)蛋白FI-RSV疫苗的toll样受体4(TLR4)激动剂佐剂
生化/生理作用
单磷酰脂质A(MPLA)是toll样受体(TLR4)的天然激动剂。它可用作免疫佐剂。单磷酰脂质A是安全的预防性药物，可用于免疫治疗。在疫苗中使用单磷酰脂质A可提高B细胞和T细胞介导免疫力。
包装
2 mL 棕色玻璃钳口盖瓶 (699800P-1 mg)
2 mL 棕色玻璃钳口盖瓶 (699800P-5 mg)
其他说明
仅供研发使用。不用于药物、家庭或其他用途。
法律信息
PHAD is a registered trademark of Avanti Polar Lipids, Inc.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Susana Lousada-Dietrich et al.
Vaccine, 29(17), 3284-3292 (2011-02-26)
GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant
Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens
Shao S, et al.
Nature Chemistry, 7(5), 438-438 (2015)
Caroline Boudousquié et al.
Vaccines, 8(1) (2020-01-18)
With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here
Katharina Richard et al.
Vaccine, 38(27), 4298-4308 (2020-05-12)
Toll-like receptors (TLRs), a family of "pattern recognition receptors," bind microbial and host-derived molecules, leading to intracellular signaling and proinflammatory gene expression. TLR4 is unique in that ligand-mediated activation requires the co-receptor myeloid differentiation 2 (MD2) to initiate two signaling
Rhea N Coler et al.
PloS one, 6(1), e16333-e16333 (2011-02-08)
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门